Advertorial about apceth Biopharma (in German) published in Transkript 9-2018 Download (pdf)
New peer-reviewed publication with the results of apceth Biopharma’s TREAT-ME 1 clinical trial
This phase I/II, first-in-class, first-in-men clinical trial tested safety, tolerability and efficacy of genetically modified mesenchymal stem cells (MSC) in the treatment of advanced, recurrent gastrointestinal cancer. Download publication: Publication_apceth Biopharma_TREAT-ME 1 clinical trial
New review article published by apceth’s preclinical experts in European Respiratory Review
Geiger S, Hirsch D, Hermann FG. Cell therapy for lung disease Eur Respir Rev. 2017 Jun 28;26(144). Print 2017, Jun 30. Download Publication – Geiger 2017 (PDF)
NEW COLLABORATIVE PEER-REVIEWED PUBLICATION
„Mesenchymal Stromal Cells Protect Endothelial Cells from Cytotoxic T Lymphocyte-Induced Lysis“
apceth enters License Option Agreement with Cynata Therapeutics Ltd
apceth, the global innovator and leader
apceth CEO
Dr. Christine Günther, apceth CEO, elected as a member of vfa bio Executive Board
“Team Munich”
apceth joins the race for “The Palo Alto Longevity Prize” under the name “Team Munich”.
Experts published
apceth experts published a book “Advances in Pharmaceutical Cell Therapy: Principles of Cell-Based Biopharmaceuticals”